Pfizer Inc. April 20 prevailed in its fight to protect its overactive bladder treatment Toviaz (fesoterodine fumarate) from generic competition until patents covering the drugs expire (Pfizer Inc. v. Sandoz Inc., 2016 BL 125982, D. Del., 1:13-cv-01110-GMS, 4/20/16).
The ruling means that no generic versions can enter the market until the patents expire.
Pfizer was “pleased with the court’s decision recognizing the validity and infringement of the Toviaz patents,” the company said in a statement e-mailed to Bloomberg BNA April 20.
Four of the patents are compound patents, all of which expire in 2019. They are U.S. Patent ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.